Form 4: Deep Track Funds Divest $22.3M in Dynavax Shares

Deep Track Biotechnology Master Fund and affiliates sold over 2 million shares of Dynavax Technologies common stock in pre-planned transactions.

Summary

• Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, and David Kroin, identified as a Director and 10% Owner of Dynavax Technologies Corp (DVAX), reported sales of common stock.
• On August 21, 2025, 1,094,994 shares were sold at a price of $11.03 per share, totaling approximately $12.08 million.
• On August 22, 2025, an additional 970,143 shares were sold at a price of $10.59 per share, totaling approximately $10.27 million.
• The total number of shares sold across both transactions was 2,065,137, with a combined value of approximately $22.35 million.
• Following these transactions, the reporting persons beneficially own 15,726,349 shares of Dynavax common stock.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.

Sentiment

Score: 4

Explanation: The sale of a substantial number of shares by a significant insider, even under a 10b5-1 plan, typically carries a negative sentiment as it suggests the insider is reducing their exposure. While the pre-planned nature mitigates some of the immediate negative signal, the sheer volume and the slight decline in sale price contribute to a moderately negative outlook.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not necessarily driven by new, negative information about the company.

Negatives

• A significant sale of 2,065,137 shares, valued at approximately $22.35 million, by a 10% owner and director could be perceived as a negative signal regarding the insider's confidence in the company's near-term stock performance.
• The average sale price decreased from $11.03 to $10.59 between the two transaction dates.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the significant insider sale as a negative signal, potentially leading to downward pressure on the stock price.
• Management: The sale by a director and 10% owner could raise questions about internal confidence, though the 10b5-1 plan provides a standard explanation.

Key Dates

Recommendation

While the significant insider sale by a 10% owner and director is a negative signal, the fact that it was executed under a Rule 10b5-1 plan suggests it was pre-scheduled and not necessarily based on new, adverse information. Given the lack of other financial or operational details in a Form 4, a 'hold' recommendation is prudent. Investors should monitor future filings and company performance for more comprehensive insights before making a 'buy' or 'sell' decision. The sale reduces insider exposure but doesn't inherently indicate a fundamental deterioration of the company's prospects.

Keywords

Dynavax Technologies, DVAX, Deep Track Biotechnology Master Fund, Deep Track Capital, David Kroin, Insider Sale, Form 4, Stock Transaction, 10% Owner, Biotechnology, Pharmaceuticals